JINS HOLDINGS Inc. (JNDOF)
USD 22.75
(0.0%)
USD 22.75
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 7.76 Billion JPY | -2.16% |
| 2022 | 6.26 Billion JPY | -12.57% |
| 2021 | 7.74 Billion JPY | -15.91% |
| 2020 | 8.42 Billion JPY | -3.42% |
| 2019 | 9.95 Billion JPY | 19.03% |
| 2018 | 8.4 Billion JPY | 7.41% |
| 2017 | 7.58 Billion JPY | 29.66% |
| 2016 | 5.8 Billion JPY | 8.67% |
| 2015 | 5.41 Billion JPY | 20.47% |
| 2014 | 4.46 Billion JPY | -36.66% |
| 2013 | 7.05 Billion JPY | 112.45% |
| 2012 | 3.32 Billion JPY | 120.32% |
| 2011 | 1.5 Billion JPY | 42.69% |
| 2010 | 1.05 Billion JPY | 89.26% |
| 2009 | 557.99 Million JPY | 10.84% |
| 2008 | 503.4 Million JPY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 3.21 Billion JPY | 47.91% |
| 2024 Q1 | 1.08 Billion JPY | 883.51% |
| 2024 Q2 | 2.18 Billion JPY | 19.81% |
| 2023 Q3 | 2.12 Billion JPY | 160.12% |
| 2023 FY | - JPY | -2.16% |
| 2023 Q4 | 185 Million JPY | -91.27% |
| 2023 Q1 | 697 Million JPY | 2.05% |
| 2023 Q2 | 815 Million JPY | 16.93% |
| 2022 Q1 | 729 Million JPY | -32.75% |
| 2022 FY | - JPY | -12.57% |
| 2022 Q4 | 683 Million JPY | -31.97% |
| 2022 Q3 | 1 Billion JPY | -33.86% |
| 2022 Q2 | 1.51 Billion JPY | 108.23% |
| 2021 Q3 | 1.43 Billion JPY | -25.51% |
| 2021 Q4 | 1.08 Billion JPY | -24.25% |
| 2021 Q1 | 743 Million JPY | -80.29% |
| 2021 Q2 | 1.92 Billion JPY | 158.55% |
| 2021 FY | - JPY | -15.91% |
| 2020 Q3 | -694 Million JPY | -133.92% |
| 2020 Q1 | 1.4 Billion JPY | -37.68% |
| 2020 Q2 | 2.04 Billion JPY | 45.21% |
| 2020 Q4 | 3.77 Billion JPY | 643.23% |
| 2020 FY | - JPY | -3.42% |
| 2019 FY | - JPY | 19.03% |
| 2019 Q3 | 2.37 Billion JPY | 48.34% |
| 2019 Q1 | 930 Million JPY | -48.36% |
| 2019 Q2 | 1.6 Billion JPY | 72.15% |
| 2019 Q4 | 2.26 Billion JPY | -4.8% |
| 2018 Q4 | 1.8 Billion JPY | -8.95% |
| 2018 Q1 | 461 Million JPY | -69.14% |
| 2018 Q2 | 1.53 Billion JPY | 233.41% |
| 2018 Q3 | 1.97 Billion JPY | 28.69% |
| 2018 FY | - JPY | 7.41% |
| 2017 FY | - JPY | 29.66% |
| 2017 Q4 | 1.49 Billion JPY | -21.12% |
| 2017 Q3 | 1.89 Billion JPY | 52.13% |
| 2017 Q2 | 1.24 Billion JPY | 69.62% |
| 2017 Q1 | 734 Million JPY | -51.99% |
| 2016 FY | - JPY | 8.67% |
| 2016 Q4 | 1.52 Billion JPY | 55.23% |
| 2016 Q3 | 985 Million JPY | 12.31% |
| 2016 Q2 | 877 Million JPY | 194.3% |
| 2016 Q1 | 298 Million JPY | -73.46% |
| 2015 Q1 | 206.63 Million JPY | -73.95% |
| 2015 Q4 | 1.12 Billion JPY | -27.43% |
| 2015 Q3 | 1.54 Billion JPY | 134.29% |
| 2015 Q2 | 660.41 Million JPY | 219.6% |
| 2015 FY | - JPY | 20.47% |
| 2014 Q4 | 793.07 Million JPY | -35.62% |
| 2014 FY | - JPY | -36.66% |
| 2014 Q3 | 1.23 Billion JPY | 73.13% |
| 2014 Q2 | 711.5 Million JPY | 209.38% |
| 2014 Q1 | 229.97 Million JPY | -81.89% |
| 2013 Q4 | 1.26 Billion JPY | 38.68% |
| 2013 Q3 | 915.67 Million JPY | -62.12% |
| 2013 FY | - JPY | 112.45% |
| 2013 Q1 | 1.31 Billion JPY | 30.19% |
| 2013 Q2 | 2.41 Billion JPY | 84.09% |
| 2012 Q3 | 573.24 Million JPY | -30.86% |
| 2012 Q4 | 1 Billion JPY | 75.94% |
| 2012 FY | - JPY | 120.32% |
| 2012 Q1 | 177.59 Million JPY | -66.83% |
| 2012 Q2 | 829.15 Million JPY | 366.88% |
| 2011 Q4 | 535.38 Million JPY | 23.35% |
| 2011 Q2 | 659.24 Million JPY | 641.12% |
| 2011 Q3 | 434.02 Million JPY | -34.16% |
| 2011 Q1 | -121.82 Million JPY | -131.22% |
| 2011 FY | - JPY | 42.69% |
| 2010 Q3 | 267.18 Million JPY | -41.25% |
| 2010 FY | - JPY | 89.26% |
| 2010 Q1 | -56.21 Million JPY | -118.44% |
| 2010 Q4 | 390.26 Million JPY | 46.06% |
| 2010 Q2 | 454.8 Million JPY | 909.02% |
| 2009 Q3 | 157.85 Million JPY | -26.7% |
| 2009 Q1 | -120.1 Million JPY | 0.0% |
| 2009 Q4 | 304.87 Million JPY | 93.13% |
| 2009 Q2 | 215.36 Million JPY | 279.31% |
| 2009 FY | - JPY | 10.84% |
| 2008 FY | - JPY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| American Medical Technologies Inc. | -963.95 Thousand USD | 805636.364% |
| Ansell Limited | 209.86 Million USD | -3600.063% |
| Ansell Limited | 206.3 Million USD | -3663.936% |
| BG Medicine, Inc. | - USD | -Infinity% |
| Biotage AB (publ) | 42.83 Million USD | -18025.667% |
| BioLife Sciences Inc. | - USD | -Infinity% |
| CB Scientific, Inc. | -1.62 Million USD | 477960.563% |
| Psykey, Inc. | -1.29 Million USD | 599573.174% |
| ConvaTec Group Plc | 455.5 Million USD | -1604.72% |
| ConvaTec Group Plc | 455.5 Million USD | -1604.72% |
| Encision Inc. | -544.19 Thousand USD | 1426978.233% |
| Golden Valley Development, Inc | -141.81 Thousand USD | 5475736.415% |
| Hear AtLast Holdings, Inc. | -109.93 Thousand USD | 7063685.918% |
| Innovative MedTech Inc. | -7.67 Million USD | 101288.235% |
| LifePoint, Inc. | -14.2 Million USD | 54774.87% |
| Medite Cancer Diagnostics, Inc. | -6.18 Million USD | 125605.091% |
| Paradigm Medical Industries, Inc. | -325 Thousand USD | 2389330.769% |
| QuantRx Biomedical Corporation | - USD | -Infinity% |
| Remedent, Inc. | -215.23 Thousand USD | 3607801.385% |
| Reflect Scientific, Inc. | -405.78 Thousand USD | 1913679.638% |
| SmileDirectClub, Inc. | -186.13 Million USD | 4271.614% |
| Sector 10, Inc. | - USD | -Infinity% |
| Shandong Weigao Group Medical Polymer Company Limited | 447.82 Million USD | -1633.939% |
| SheerVision, Inc. | -110.53 Thousand USD | 7025278.457% |
| United Health Products, Inc. | -2.5 Million USD | 310425.176% |
| Vasamed, Inc. | -4.57 Million USD | 169847.48% |
| Wearable Health Solutions, Inc. | -2.26 Million USD | 343572.214% |
| Yubo International Biotech Limited | -1.17 Million USD | 659443.832% |